What is the major therapeutic use of palivizumab?

The primary therapeutic use of palivizumab is to prevent respiratory syncytial virus (RSV) infection in high-risk infants. This monoclonal antibody is specifically designed to provide passive immunity, offering protection against RSV, which can lead to severe respiratory illnesses in vulnerable populations, especially infants born prematurely or those with certain underlying health conditions. By administering palivizumab before the RSV season, healthcare providers can significantly reduce the incidence and severity of infection in these high-risk patients, helping to prevent hospitalizations and complications associated with RSV. This targeted use showcases palivizumab's role in pediatric healthcare, particularly regarding viral respiratory infections.